



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
14.04.2021 Bulletin 2021/15

(45) Date of publication and mention
of the grant of the patent:
10.03.2021 Bulletin 2021/10

(21) Application number: **16777107.0**

(22) Date of filing: **04.04.2016**

(51) Int Cl.:
A61P 35/00 ^(2006.01) **A61K 38/00** ^(2006.01)
C07K 14/00 ^(2006.01) **C07K 14/705** ^(2006.01)
C07K 16/10 ^(2006.01) **C07K 16/28** ^(2006.01)
C07K 14/435 ^(2006.01) **G01N 33/574** ^(2006.01)
A61K 38/17 ^(2006.01)

(86) International application number:
PCT/US2016/025868

(87) International publication number:
WO 2016/164305 (13.10.2016 Gazette 2016/41)

(54) **DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF**
DE-NOVO-BINDUNGSDOMÄNE MIT POLYPEPTIDEN UND VERWENDUNGEN DAVON
POLYPEPTIDES CONTENANT UN DOMAINE DE LIAISON DE NOVO ET LEURS UTILISATIONS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **06.04.2015 US 201562143772 P**

(43) Date of publication of application:
14.02.2018 Bulletin 2018/07

(60) Divisional application:
21155053.8

(73) Proprietors:
• **Subdomain, LLC**
Washington, DC 20015 (US)
• **Arcellx, Inc.**
Gaithersburg, MD 20878 (US)

(72) Inventors:
• **LAFLEUR, David, William**
Washington, DC 20015 (US)
• **HILBERT, David, M.**
Gaithersburg, MD 20878 (US)

(74) Representative: **D Young & Co LLP**
120 Holborn
London EC1N 2DY (GB)

(56) References cited:
WO-A1-2010/124829 WO-A1-2014/138805
US-A1- 2014 271 582

- **PER-ÅKE NYGREN: "Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold : Affibody binding proteins", FEBS JOURNAL, vol. 275, no. 11, 24 April 2008 (2008-04-24), pages 2668-2676, XP055504842, GB ISSN: 1742-464X, DOI: 10.1111/j.1742-4658.2008.06438.x**
- **NOAD R ET AL: "Virus-like particles as immunogens", TRENDS IN MICROBIOLOGY, ELSEVIER SCIENCE LTD., KIDLINGTON, GB, vol. 11, no. 9, 1 September 2003 (2003-09-01), pages 438-444, XP003004438, ISSN: 0966-842X, DOI: 10.1016/S0966-842X(03)00208-7**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- ANDREAS PLÜCKTHUN: "Designed Ankyrin Repeat Proteins (DARPs): Binding Proteins for Research, Diagnostics, and Therapy", ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, vol. 55, no. 1, 6 January 2015 (2015-01-06), pages 489-511, XP055217451, ISSN: 0362-1642, DOI: 10.1146/annurev-pharmtox-010611-134654
- DAVID LAFLEUR ET AL: "Monoclonal antibody therapeutics with up to five specificities: Functional enhancement through fusion of target-specific peptides", MABS, vol. 5, no. 2, 1 March 2013 (2013-03-01), pages 208-218, XP055196030, ISSN: 1942-0862, DOI: 10.4161/mabs.23043
- PLÜCKTHUN.: 'Designed ankyrin repeat proteins (DARPs): binding proteins for research, diagnostics, and therapy.' ANNU REV PHARMACOL TOXICOL. vol. 55, January 2015, pages 489 - 511, XP055217451
- WALKER ET AL.: 'Targeting high-risk pediatric solid tumors with CAR T cells directed against ALK (anaplastic lymphoma kinase, CD 246).' J IMMUNOTHER CANCER vol. 2, no. SUPPL, 2014, page P40, XP021202601
- MARDIROS ET AL.: 'T cells expressing CD 123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.' BLOOD vol. 122, no. 18, 2013, pages 3138 - 3148, XP002727946
- DATABASE UNIPROT [Online] 07 January 2015 'Cytoplasmic dynein 2 heavy chain 1.', XP055488729 Retrieved from UNIPROTKB Database accession no. 9ZSS7